Epithelial growth factor receptor status in primary and recurrent ovarian cancer

• Published in: Modern pathology Vol. 19; no. 4; pp. 607 - 610
• Main Authors: Stadlmann, Sylvia, Gueth, Uwe, Reiser, Ulrich, Diener, Pierre-Andre, Zeimet, Alain Gustave, Wight, Edward, Mirlacher, Martina, Sauter, Guido, Mihatsch, Michael J, Singer, Gad
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2006; Elsevier Limited
• Subjects: Adult; Aged; amplification; Cystadenocarcinoma, Serous - genetics; Cystadenocarcinoma, Serous - metabolism; Cystadenocarcinoma, Serous - pathology; epidermal growth factor receptor; ErbB Receptors - analysis; ErbB Receptors - genetics; Female; fluorescence in situ hybridization; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Middle Aged; Mutation; Neoplasm Recurrence, Local; Ovarian cancer; Ovarian Neoplasms - genetics; Ovarian Neoplasms - metabolism; Ovarian Neoplasms - pathology; Tissue Array Analysis; tissue microarray; fluorescence in situ hybridization; amplification; mutation; ovarian cancer; tissue microarray; epidermal growth factor receptor
• ISSN: 0893-3952; 1530-0285
• DOI: 10.1038/modpathol.3800575

Success of epidermal growth factor receptor (EGFR) targeting agents in different cancer types is related to EGFR gene mutations and/or copy number gains. We investigated the EGFR gene status and protein expression by DNA mutational analysis, fluorescence in situ hybridization (FISH), and immunohistochemistry in tumor tissues from 80 patients with primary and corresponding recurrent ovarian serous carcinomas. The patients were classified into six groups with ascending EGFR gene copy numbers. EGFR amplification and high polysomy (FISH+) was present in a significant fraction of the primary (20%) and recurrent (22%) ovarian carcinomas. On mutational analysis, only one tumor with a silent EGFR mutation was observed, and this was the only carcinoma with high-level amplification. EGFR protein immunoexpression was seen in 28% of primary and 33% of recurrent carcinomas and correlated to amplification in the primary tumors (P=0.003). In recurrent carcinoma, moderate and strong EGFR expression was associated with amplification (P=0.034). These molecular events potentially have impact on the responsiveness to EGFR targeting agents in ovarian cancer.